SI3021859T1 - Onkolitični adenovirusi, opremljeni s heterolognimi geni - Google Patents

Onkolitični adenovirusi, opremljeni s heterolognimi geni Download PDF

Info

Publication number
SI3021859T1
SI3021859T1 SI201430609T SI201430609T SI3021859T1 SI 3021859 T1 SI3021859 T1 SI 3021859T1 SI 201430609 T SI201430609 T SI 201430609T SI 201430609 T SI201430609 T SI 201430609T SI 3021859 T1 SI3021859 T1 SI 3021859T1
Authority
SI
Slovenia
Prior art keywords
seq
adenovirus according
sequence
adenovirus
transgenic
Prior art date
Application number
SI201430609T
Other languages
English (en)
Inventor
Brian Robert Champion
Alice Claire Noel Brown
Kerry David Fisher
Tamara Nicolson
Original Assignee
Psioxus Therapeutics Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB201318885A external-priority patent/GB201318885D0/en
Priority claimed from GBGB1318880.0A external-priority patent/GB201318880D0/en
Priority claimed from GBGB1322851.5A external-priority patent/GB201322851D0/en
Priority claimed from GB201401159A external-priority patent/GB201401159D0/en
Priority claimed from GB201406470A external-priority patent/GB201406470D0/en
Application filed by Psioxus Therapeutics Limited filed Critical Psioxus Therapeutics Limited
Publication of SI3021859T1 publication Critical patent/SI3021859T1/sl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/76Viruses; Subviral particles; Bacteriophages
    • A61K35/761Adenovirus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5256Virus expressing foreign proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Claims (18)

  1. Onkolitični adenovirusi, opremeljeni s heterolognimi geni Patentni zahtevki
    1. Replikacijsko kompetenten onkolitični adenovirus skupine B, ki obsega zaporedje s formulo (I): 5 ’ITR-B ] -Ba-B2-Bx-Bb-B y-B3-3 ’ITR kjer: Bi obsega: E1A, E1B ali E1A-E1B; Ba obsega: -E2B-L1-L2-L3-E2A-L4; B2 je vez ali obsega: E3; Bx je vez ali DNA zaporedje, ki obsega: restrikcijsko mesto, enega ali več transgenov ali oba; Bb obsega L5; By obsega transgensko kaseto, ki obsega transgen in spojitveno ("splice") akceptorsko zaporedje; in B3 je vez ali obsega: E4, kjer je transgenska kaseta pod kontrolo endogenega promotorja, izbranega iz skupine, ki jo sestavljata E4 in poglavitni pozni promotor, in kjer transgenska kaseta obsega terapevtski gen, ki kodira material, izbran iz skupine, ki jo sestavljajo RNAi zaporedje, protein, protitelo ali njegov vezavni fragment, kemokin, citokin, imunomodulator in encim.
  2. 2. Replikacijsko kompetenten adenovirus po zahtevku 1, kjer je promotor poglavitni pozni promotor.
  3. 3. Replikacijsko kompetenten adenovirus po zahtevku 1 ali 2, kjer BY tudi obsega zaporedje, prikazano v SEQ ID NO: 11, ali DNA zaporedje, ki hibridizira nanj pod ostrimi pogoji.
  4. 4. Replikacijsko kompetenten adenovirus po katerem koli od zahtevkov od 1 do 3, kjer je spojitveni ("splice") akceptor izbran izmed CAGG, SEQ ID NO: 17 in SEQ ID NO: 18.
  5. 5. Replikacijsko kompetenten adenovirus po katerem koli od zahtevkov od 1 do 4, kjer transgenska kaseta nadalje obsega interno ribosomsko vstopno zaporedje ali 2A peptid z visoko samo-cepitveno učinkovitostjo.
  6. 6. Replikacijsko kompetenten adenovirus po katerem koli od zahtevkov od 1 do 5, kjer transgen nadalje obsega Kozak zaporedje.
  7. 7. Adenovirus po katerem koli od zahtevkov od 1 do 6, kjer transgenska kaseta nadalje obsega poliadenilacijsko zaporedje.
  8. 8. Adenovirus po katerem koli od zahtevkov od 1 do 7, kjer transgenska kaseta nadalje obsega restrikcijsko mesto na 3' koncu DNA zaporedja in/ali na 5' koncu DNA zaporedja.
  9. 9. Adenovirus po katerem koli od zahtevkov od 1 do 8, kjer vsaj ena transgenska kaseta kodira monocistronsko mRNA ali policistronsko mRA.
  10. 10. Adenovirus po zahtevku od 1 do 9, kjer je protitelo ali njegov vezavni fragment specifičen za 0X40, 0X40 ligand, CD27, CD28, CD30, CD40, CD40 ligand, CD70, CD137, GITR, 4-1BB, ICOS, ICOS ligand, CTLA-4, PD-1, PD-L1, PD-L2, VISTA, B7-H3, B7-H4, HVEM, ILT-2, ILT-3, ILT-4, TIM-3, LAG-3, BTLA, LIGHT, CD160, CTLA-4, PD-1, PD-L1, PD-L2.
  11. 11. Adenovirus po katerem koli od zahtevkov od 1 do 10, kjer je kodirani protein citokin, neodvisno izbran iz skupine, ki jo sestavljajo IL-la, IL-Ιβ, IL-6, IL-9, IL-12, IL-13, IL-17, IL-18, IL-22, IL-23, IL-24, IL-25, IL-26, IL-27, IL-33, IL-35, IL-2, IL-4, IL-5, IL-7, IL-10, IL-15, IL-21, IL-25, IL-1RA, IFNa, IFNp, IFNy, TNFa, TGFp, limfotoksin a (LTA) in GM-CSF.
  12. 12. Adenovirus po katerem koli od zahtevkov od 1 do 11, kjer je kodirani protein kemokin, neodvisno izbran iz skupine, ki jo sestavljajo IL-8, CCL5, CCL17, CCL20, CCL22, CXCL9, CXCL10, CXCL11, CXCL13, CXCL12, CCL2, CCL19, CCL21, CXCR2, CCR2, CCR4, CCR5, CCR6, CCR7, CCR8, CXCR3, CXCR4, CXCR5 in CRTH2.
  13. 13. Adenovirus po katerem koli od zahtevkov od 1 do 12, kjer je transgen reporterski gen, na primer natrijev jodid simporter, intracelulami metaloproteini, HSVl-tk, GFP-ji, luciferaza ali estrogenski receptor.
  14. 14. Adenovirus po katerem koli od zahtevkov od 1 do 13, kjer je adenovirus Adi 1.
  15. 15. Adenovirus po katerem koli od zahtevkov od 1 do 13, kjer je adenovirus virus, znan kot EnAd, prikazan v zaporedju ID No: 12.
  16. 16. Adenovirus po katerem koli od zahtevkov 1 do 15, kjer virus obsega zaporedje s SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 46, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 63, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69 ali SEQ ID NO: 73.
  17. 17. Sestavek, ki obsega adenovirus po katerem koli od zahtevkov od 1 do 16.
  18. 18. Adenovirus po katerem koli od zahtevkov od 1 do 16 ali sestavek po zahtevku 17 za uporabo v zdravljenju.
SI201430609T 2013-10-25 2014-10-24 Onkolitični adenovirusi, opremljeni s heterolognimi geni SI3021859T1 (sl)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB201318885A GB201318885D0 (en) 2013-10-25 2013-10-25 Adenovirus
GBGB1318880.0A GB201318880D0 (en) 2013-10-25 2013-10-25 Adenovirus
GBGB1322851.5A GB201322851D0 (en) 2013-12-23 2013-12-23 Method
GB201401159A GB201401159D0 (en) 2014-01-23 2014-01-23 Adenovirus
GB201406470A GB201406470D0 (en) 2014-04-10 2014-04-10 Virus
EP14799117.8A EP3021859B1 (en) 2013-10-25 2014-10-24 Oncolytic adenoviruses armed with heterologous genes
PCT/EP2014/072919 WO2015059303A1 (en) 2013-10-25 2014-10-24 Oncolytic adenoviruses armed with heterologous genes

Publications (1)

Publication Number Publication Date
SI3021859T1 true SI3021859T1 (sl) 2018-04-30

Family

ID=51900851

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201430609T SI3021859T1 (sl) 2013-10-25 2014-10-24 Onkolitični adenovirusi, opremljeni s heterolognimi geni

Country Status (30)

Country Link
US (3) US9987314B2 (sl)
EP (3) EP3831398A1 (sl)
KR (1) KR102272932B1 (sl)
CN (2) CN114457044A (sl)
AU (1) AU2014338864C1 (sl)
CA (2) CA3183645A1 (sl)
CL (1) CL2016000959A1 (sl)
CY (1) CY1119955T1 (sl)
DK (1) DK3021859T3 (sl)
EA (1) EA036414B1 (sl)
ES (1) ES2661132T3 (sl)
HR (1) HRP20180317T1 (sl)
HU (1) HUE035875T2 (sl)
IL (2) IL244944B (sl)
LT (1) LT3021859T (sl)
MX (1) MX2016005170A (sl)
MY (1) MY175614A (sl)
NO (1) NO3021859T3 (sl)
NZ (1) NZ718931A (sl)
PE (1) PE20160951A1 (sl)
PH (1) PH12016500759B1 (sl)
PL (1) PL3021859T3 (sl)
PT (1) PT3021859T (sl)
RS (1) RS57043B1 (sl)
SA (1) SA516371011B1 (sl)
SG (2) SG11201602887QA (sl)
SI (1) SI3021859T1 (sl)
TR (1) TR201802728T4 (sl)
WO (1) WO2015059303A1 (sl)
ZA (1) ZA201603646B (sl)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11173186B2 (en) 2013-06-14 2021-11-16 Psioxus Therapeutics Limited Dosing regime and formulations for type B adenovirus
RS57043B1 (sr) * 2013-10-25 2018-05-31 Psioxus Therapeutics Ltd Onkolitički adenovirusi snabdeveni heterologus genima
GB201406608D0 (en) 2014-04-12 2014-05-28 Psioxus Therapeutics Ltd Virus
GB201510197D0 (en) 2014-06-12 2015-07-29 Psioxus Therapeutics Ltd Method of treating ovarian cancer
EP3186366A2 (en) 2014-08-27 2017-07-05 Psioxus Therapeutics Limited A process for the production of adenovirus
US10973914B2 (en) 2015-02-20 2021-04-13 Ohio State Innovation Foundation Bivalent antibody directed against NKG2D and tumor associated antigens
EP3280437A4 (en) 2015-04-06 2018-09-12 Jianhua Yu Egfr-directed car therapy for glioblastoma
BR112017023171A2 (pt) * 2015-04-30 2018-07-17 Psioxus Therapeutics Limited adenovírus oncolítico que codifica proteína b7
EA201891021A1 (ru) * 2015-12-17 2018-11-30 Псайоксус Терапьютикс Лимитед Аденовирус группы b, кодирующий антитело к комплексу tcr или фрагмент указанного антитела
ES2831080T5 (es) 2016-01-08 2023-10-30 Replimune Ltd Virus oncolítico modificado
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
EP4273252A3 (en) * 2016-08-29 2024-04-17 Akamis Bio Limited Adenovirus armed with bispecific t cell engager (bite)
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
WO2018083258A1 (en) * 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding at least three transgenes
WO2018083259A1 (en) * 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding transgenes
WO2018083257A1 (en) * 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding transgenes
GB201700350D0 (en) * 2017-01-09 2017-02-22 Replimune Ltd Altered virus
WO2018170763A1 (zh) * 2017-03-22 2018-09-27 深圳市博奥康生物科技有限公司 ILA 基因的 RNAi 表达载体及其构建方法和应用
TWI796329B (zh) 2017-04-07 2023-03-21 美商默沙東有限責任公司 抗-ilt4抗體及抗原結合片段
PT3630143T (pt) * 2017-06-01 2023-08-29 Akamis Bio Ltd Vírus oncolítico e método
BR112020007321A2 (pt) 2017-10-20 2020-09-29 F. Hoffmann-La Roche Ag conjugado de anticorpo, uso, uso de um marcador isotópico estável e kit
GB201801614D0 (en) 2018-01-31 2018-03-14 Psioxus Therapeutics Ltd Formulation
AU2019299555A1 (en) * 2018-07-04 2021-02-25 Cytoimmune Therapeutics, Inc. Compositions and methods for immunotherapy targeting FLT3, PD-1, and/or PD-L1
KR20240067973A (ko) 2018-07-11 2024-05-17 액팀 테라퓨틱스, 인코퍼레이티드 조작된 면역자극성 박테리아 균주 및 이의 용도
WO2020052551A1 (en) * 2018-09-10 2020-03-19 Genesail Biotech (Shanghai) Co. Ltd. A modified oncolytic virus, composition and use thereof
EP3927833A4 (en) * 2019-02-21 2022-11-30 Unleash Immuno Oncolytics, Inc. ONCOLYTIC ADENOVIRAL VECTOR AND METHODS OF USE
CA3176660A1 (en) 2019-02-27 2020-09-03 Actym Therapeutics, Inc. Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
US12024709B2 (en) 2019-02-27 2024-07-02 Actym Therapeutics, Inc. Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
GB201909081D0 (en) 2019-06-25 2019-08-07 Psioxus Therapeutics Ltd Method
WO2021097144A2 (en) 2019-11-12 2021-05-20 Actym Therapeutics, Inc. Immunostimulatory bacteria delivery platforms and their use for delivery of therapeutic products
KR20210118760A (ko) * 2020-03-23 2021-10-01 (주)큐리진 AR 및 mTOR를 이중 특이적으로 표적하는 핵산분자를 포함하는 항암바이러스
KR20210118757A (ko) * 2020-03-23 2021-10-01 (주)큐리진 STAT3 및 mTOR를 이중 특이적으로 표적하는 핵산서열을 포함한 항암 바이러스
KR102601875B1 (ko) * 2020-03-25 2023-11-14 (주)큐리진 면역 회피성 항종양 아데노바이러스
JP2023539454A (ja) 2020-08-12 2023-09-14 アクティム・セラピューティクス・インコーポレイテッド 免疫刺激細菌ベースのワクチン、治療薬およびrnaデリバリープラットフォーム
IL303899A (en) * 2020-12-22 2023-08-01 Ensoma Inc Adenoviral gene therapy vectors
WO2022135357A1 (en) * 2020-12-22 2022-06-30 Sunshine Lake Pharma Co., Ltd. A hIL7/hCCL19 DOUBLE GENE RECOMBINANT ONCOLYTIC VIRUS AND ITS PREPARATION METHOD AND USE
GB202102049D0 (en) 2021-02-13 2021-03-31 Psioxus Therapeutics Ltd Viruses
CA3235418A1 (en) 2021-11-09 2023-05-19 Actym Therapeutics, Inc. Immunostimulatory bacteria for converting macrophages into a phenotype amenable to treatment, and companion diagnostic for identifying subjects for treatment
WO2023168436A1 (en) * 2022-03-03 2023-09-07 Board Of Regents, The University Of Texas System Anti-cd19 and anti-cd79b chimeric antigen receptors and methods of use thereof
CN116836283B (zh) * 2022-05-17 2024-05-07 苏州万灏生物科技有限公司 具有多种免疫调节因子的增强型溶瘤病毒及其制备方法和应用

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0170269A3 (en) 1984-08-02 1987-09-23 Kao Corporation Medicated cosmetic compositions
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
WO1992002551A1 (en) 1990-08-02 1992-02-20 B.R. Centre Limited Methods for the production of proteins with a desired function
GB9113120D0 (en) 1991-06-18 1991-08-07 Kodak Ltd Photographic processing apparatus
US5358866A (en) 1991-07-03 1994-10-25 The United States Of America As Represented By The Department Of Health And Human Services Cytosine deaminase negative selection system for gene transfer techniques and therapies
US5846945A (en) 1993-02-16 1998-12-08 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
FR2705361B1 (fr) 1993-05-18 1995-08-04 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
HU216871B (hu) 1993-07-13 1999-09-28 Rhone-Poulenc Rorer S.A. Defektív adenovírusvektorok és génterápiai alkalmazásuk
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5830686A (en) 1994-01-13 1998-11-03 Calydon Tissue-specific enhancer active in prostate
US5677170A (en) 1994-03-02 1997-10-14 The Johns Hopkins University In vitro transposition of artificial transposons
FR2730504B1 (fr) * 1995-02-13 1997-03-28 Rhone Poulenc Rorer Sa Procede de preparation de genomes d'adenovirus recombinants
DE19648650C2 (de) 1996-01-29 1998-07-02 Schering Ag Puffersysteme und deren Verwendung zur Stabilisierung pharmazeutischer Zubereitung
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
US5877011A (en) 1996-11-20 1999-03-02 Genzyme Corporation Chimeric adenoviral vectors
CN1242051A (zh) 1996-12-31 2000-01-19 昂尼克斯药物公司 用于肿瘤治疗和预防的致细胞病变病毒
EP1036183B1 (en) 1997-02-20 2007-10-03 The Johns Hopkins University School Of Medicine Mutations in atp-dependent transposition proteins that reduce target-site specificity
US20030044384A1 (en) 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
AU9603898A (en) 1997-10-09 1999-05-03 Pro-Virus, Inc. Treatment of neoplasms with viruses
US6291214B1 (en) 1998-05-11 2001-09-18 Glaxo Wellcome Inc. System for generating recombinant viruses
US20020019051A1 (en) 1998-05-27 2002-02-14 Monika Lusky Chimeric adenoviral vectors
US20030017138A1 (en) 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
CN1110553C (zh) 1998-07-15 2003-06-04 杭州赛狮生物技术开发有限公司 基因工程腺病毒及其用途
JP2002523105A (ja) * 1998-08-27 2002-07-30 アバンテイス・フアルマ・エス・アー 異種遺伝子の運搬用の標的化アデノウイルスベクター
AU767975B2 (en) 1998-09-11 2003-11-27 Genvec, Inc. Alternatively targeted adenovirus
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
CA2354024C (en) 1998-12-09 2009-12-22 Jeffrey Schlom A recombinant vector expressing multiple costimulatory molecules and uses thereof
DE60029195T2 (de) 1999-02-22 2007-06-28 Transgene S.A. Verfahren zur Gewinnung von purifizierter Virenzusammensetzung
BR0009595A (pt) 1999-04-09 2001-12-26 Aventis Pharma Sa Composição lìquida ou congelada e utilizaçãoterapêutica ou profilática da mesma
DE60043126D1 (de) 1999-05-17 2009-11-19 Crucell Holland Bv Von Adenovirus abgeleitete Gentransfervehikel, die zumindest ein Element des Adenovirus Typ 35 enthalten
DE60018920T2 (de) 1999-06-01 2006-04-13 University Of Washington, Seattle Rekombinante adenovirale vektoren, die chimäre fiberproteine exprimieren, für die zellspezifische infektion und genomische integration
JP4827353B2 (ja) 1999-08-09 2011-11-30 ターゲティッド ジェネティクス コーポレイション 鎖内塩基対を形成するような配列の設計による、組換えウイルスベクターからの一本鎖の異種ヌクレオチド配列の発現の増大
US7396679B2 (en) 1999-11-15 2008-07-08 Onyx Pharmaceuticals, Inc. Oncolytic adenovirus
DE60107203T3 (de) 2000-01-21 2009-07-23 Biovex Ltd. Herpes-virusstämme für die gentherapie
US7456009B2 (en) 2000-03-07 2008-11-25 Merck & Co., Inc. Adenovirus formulations
AU2001265154A1 (en) 2000-05-31 2001-12-11 Genvec, Inc. Method and composition for targeting an adenoviral vector
US20030031675A1 (en) 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
US6965018B2 (en) 2000-06-06 2005-11-15 Bristol-Myers Squibb Company Antibodies directed to B7-related polypeptide, BSL-2
WO2002053759A1 (en) 2001-01-04 2002-07-11 Wadell Goeran Viral vector for gene therapy
US20050175589A1 (en) 2001-07-13 2005-08-11 Btg International Limited Anti-neoplastic viral agents
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
EP1327688A1 (en) 2002-01-14 2003-07-16 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Adenoviruses with enhanced lytic potency
CA2474777A1 (en) 2002-02-01 2003-08-07 Transgene S.A. Adenoviral vectors for modulating the cellular activities associated with pods
US7858367B2 (en) 2002-04-30 2010-12-28 Duke University Viral vectors and methods for producing and using the same
JP4603894B2 (ja) 2002-12-03 2010-12-22 ユセベ ファルマ ソシエテ アノニム 抗体産生細胞を同定するためのアッセイ
US20040167088A1 (en) 2003-02-25 2004-08-26 Genvec, Inc. Method of using adenoviral vectors with increased persistence in vivo
US20040213764A1 (en) 2003-03-28 2004-10-28 William Wold Adenovirus replication-competent vectors expressing trail
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
US7989594B2 (en) 2003-07-01 2011-08-02 Celltech R & D Limited Modified antibody fab fragments
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
CA2527369A1 (en) 2003-07-18 2005-02-03 Onyx Pharmaceuticals, Inc. Subgroup b adenoviral vectors for treating disease
US20050186178A1 (en) 2003-08-28 2005-08-25 Ennist David L. Oncolytic adenoviral vectors encoding GM-CSF
NZ546173A (en) 2003-10-16 2009-04-30 Micromet Ag Multispecific deimmunized CD3-binders
WO2005086922A2 (en) * 2004-03-10 2005-09-22 Board Of Regents, University Of Texas System Oncolytic adenovirus armed with therapeutic genes
WO2005107474A2 (en) * 2004-04-30 2005-11-17 Introgen Therapeutics, Inc. Oncolytic adenovirus armed with therapeutic genes
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
WO2005118825A2 (en) * 2004-05-26 2005-12-15 Schering Aktiengesellschaft Chimeric adenoviruses for use in cancer treatment
CN100361710C (zh) 2004-06-07 2008-01-16 成都康弘生物科技有限公司 肿瘤细胞专一表达免疫调节因子gm-csf的溶瘤性腺病毒重组体的构建及其应用
US20060292682A1 (en) 2004-07-22 2006-12-28 Hawkins Lynda K Addition of transgenes into adenoviral vectors
CA2589602A1 (en) 2004-09-01 2006-04-13 Genvec, Inc. Adenoviral vectors able to transduce apcs, potential use in immune response generation
US7550296B2 (en) 2004-12-01 2009-06-23 Bayer Schering Pharma Ag Generation of replication competent viruses for therapeutic use
US20060205080A1 (en) 2005-03-01 2006-09-14 David Frey Formulations for therapeutic viruses having enhanced storage stability
CA2620495A1 (en) 2005-08-31 2007-03-08 Genvec, Inc. Adenoviral vector-based malaria vaccines
CN1961961B (zh) 2005-11-11 2010-05-26 深圳市源兴生物医药科技有限公司 一种药物制剂及其制备方法
DE102005055128B4 (de) 2005-11-15 2015-04-02 Universität Rostock Viraler Vektor, dessen Verwendung zur Therapie von Leberzellkarzinomen und pharmazeutische Mittel umfassend den Vektor
ES2304281B1 (es) 2006-02-01 2009-08-12 Dnatrix Inc. Adenovirus oncoliticos para el tratamiento del cancer.
CA2673520A1 (en) 2006-12-22 2008-07-03 Bayer Schering Pharma Aktiengesellschaft Generation of oncolytic adenoviruses and uses thereof
ES2622460T3 (es) 2007-09-26 2017-07-06 Ucb Biopharma Sprl Fusiones de anticuerpos con doble especificidad
US20110034560A1 (en) 2008-01-29 2011-02-10 Sven Jacobson Liquid formulations of compounds active at sulfonylurea receptors
EP2296678A4 (en) 2008-05-27 2012-03-21 Oncolytics Biotech Inc MODULATION OF INTERSTITIAL PRESSURE AND ONCOLYTIC VIRUS RELIEF AND DISTRIBUTION
WO2010035012A1 (en) 2008-09-26 2010-04-01 Ucb Pharma S.A. Biological products
EP2370467B1 (en) 2008-10-01 2016-09-07 Amgen Research (Munich) GmbH Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxc d3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody
ES2385251B1 (es) 2009-05-06 2013-05-06 Fundació Privada Institut D'investigació Biomèdica De Bellvitge Adenovirus oncolíticos para el tratamiento del cáncer.
US20100297072A1 (en) 2009-05-19 2010-11-25 Depinho Ronald A Combinations of Immunostimulatory Agents, Oncolytic Virus, and Additional Anticancer Therapy
WO2011043719A1 (en) 2009-10-05 2011-04-14 Ya-Fang Mei Replicating viral vectors for gene therapy
KR101957616B1 (ko) 2010-08-16 2019-03-12 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 아데노바이러스 조립 방법
JP2014500004A (ja) 2010-09-24 2014-01-09 オンコス セラピュティックス オサケ ユキチュア 抗ctla−4モノクローナル抗体をコードする腫瘍溶解性アデノウイルスベクター
CA2837975C (en) 2011-08-23 2022-04-05 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
JP2015507604A (ja) 2011-11-14 2015-03-12 リジェネレイティブ サイエンシーズ, エルエルシー 懸濁粒子送達システムおよび方法
CN102586327B (zh) 2012-01-18 2013-09-11 陕西师范大学 一步法构建携带外源基因的d24纤维蛋白修饰的条件复制型腺病毒载体及其应用
RU2737765C2 (ru) 2012-05-04 2020-12-02 Пфайзер Инк. Простатоассоциированные антигены и иммунотерапевтические схемы на основе вакцин
US9314519B2 (en) 2012-08-21 2016-04-19 Intervet Inc. Liquid stable virus vaccines
US20160000842A1 (en) 2013-03-05 2016-01-07 Baylor College Of Medicine Oncolytic virus
WO2015040234A1 (en) 2013-09-23 2015-03-26 Crucell Holland B.V. Adenovirus formulations
GB201322851D0 (en) 2013-12-23 2014-02-12 Psioxus Therapeutics Ltd Method
GB201318793D0 (en) 2013-10-24 2013-12-11 Plaquetec Ltd Vascular Biomarkers
RS57043B1 (sr) 2013-10-25 2018-05-31 Psioxus Therapeutics Ltd Onkolitički adenovirusi snabdeveni heterologus genima
CN106029889A (zh) 2013-11-22 2016-10-12 德那翠丝有限公司 表达免疫细胞刺激受体激动剂的腺病毒
EP3560954B1 (en) 2014-04-03 2021-08-04 IGM Biosciences, Inc. Modified j-chain
GB201406608D0 (en) 2014-04-12 2014-05-28 Psioxus Therapeutics Ltd Virus
EP3186366A2 (en) 2014-08-27 2017-07-05 Psioxus Therapeutics Limited A process for the production of adenovirus
GB201503500D0 (en) 2015-03-02 2015-04-15 Ucl Business Plc Cell
CN107406859A (zh) 2015-03-17 2017-11-28 倾斜生物医疗公司 编码双特异性抗体的溶瘤腺病毒及与其相关的方法和用途
BR112017023171A2 (pt) 2015-04-30 2018-07-17 Psioxus Therapeutics Limited adenovírus oncolítico que codifica proteína b7
EA201891021A1 (ru) 2015-12-17 2018-11-30 Псайоксус Терапьютикс Лимитед Аденовирус группы b, кодирующий антитело к комплексу tcr или фрагмент указанного антитела
EP4273252A3 (en) 2016-08-29 2024-04-17 Akamis Bio Limited Adenovirus armed with bispecific t cell engager (bite)
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
KR20190099194A (ko) 2016-10-20 2019-08-26 알파인 이뮨 사이언시즈, 인코포레이티드 분비가능한 변이체 면역조절 단백질 및 조작된 세포 치료
WO2018083258A1 (en) 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding at least three transgenes
WO2018083259A1 (en) 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding transgenes
WO2018083257A1 (en) 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding transgenes
GB201801614D0 (en) 2018-01-31 2018-03-14 Psioxus Therapeutics Ltd Formulation

Also Published As

Publication number Publication date
US20180311291A1 (en) 2018-11-01
AU2014338864B2 (en) 2019-11-21
AU2014338864A1 (en) 2016-05-05
PL3021859T3 (pl) 2018-06-29
US20160331793A1 (en) 2016-11-17
AU2014338864A8 (en) 2018-08-23
PT3021859T (pt) 2018-03-09
CA2927968A1 (en) 2015-04-30
CY1119955T1 (el) 2018-12-12
CA3183645A1 (en) 2015-04-30
EP3021859B1 (en) 2017-11-29
NZ718931A (en) 2022-10-28
WO2015059303A1 (en) 2015-04-30
CL2016000959A1 (es) 2016-12-02
HUE035875T2 (hu) 2018-06-28
ZA201603646B (en) 2017-09-27
EP3372236A1 (en) 2018-09-12
AU2014338864C1 (en) 2020-07-16
EP3021859A1 (en) 2016-05-25
PH12016500759A1 (en) 2016-05-30
US11938159B2 (en) 2024-03-26
EA201690545A1 (ru) 2016-09-30
DK3021859T3 (en) 2018-03-05
CN108064159A (zh) 2018-05-22
BR112016008973A2 (pt) 2017-09-19
NO3021859T3 (sl) 2018-04-28
PH12016500759B1 (en) 2016-05-30
CN114457044A (zh) 2022-05-10
US11439678B2 (en) 2022-09-13
IL244944B (en) 2019-09-26
TR201802728T4 (tr) 2018-03-21
US9987314B2 (en) 2018-06-05
SA516371011B1 (ar) 2020-08-13
KR20160067184A (ko) 2016-06-13
MY175614A (en) 2020-07-01
LT3021859T (lt) 2018-06-11
SG11201602887QA (en) 2016-05-30
SG10201804030WA (en) 2018-07-30
CA2927968C (en) 2023-02-21
MX2016005170A (es) 2017-02-02
HRP20180317T1 (hr) 2018-07-13
ES2661132T3 (es) 2018-03-27
EP3831398A1 (en) 2021-06-09
KR102272932B1 (ko) 2021-07-05
CN108064159B (zh) 2021-12-10
PE20160951A1 (es) 2016-09-17
EA036414B1 (ru) 2020-11-09
IL244944A0 (en) 2016-05-31
US20210187047A1 (en) 2021-06-24
RS57043B1 (sr) 2018-05-31
IL269304A (en) 2019-11-28
IL269304B (en) 2020-06-30

Similar Documents

Publication Publication Date Title
SI3021859T1 (sl) Onkolitični adenovirusi, opremljeni s heterolognimi geni
WO2015155370A4 (en) Group b adenovirus modified in the e4orf4 region
HRP20200439T1 (hr) Onkolitički adenovirus koji kodira protein b7
JP2019502379A5 (sl)
Gallagher et al. Human interleukin-19 and its receptor: a potential role in the induction of Th2 responses
Rothe et al. Tumor necrosis factor receptors-structure and function
JP2019534036A5 (sl)
JP2019508017A5 (sl)
JP2020520922A (ja) T細胞療法を向上させるための、哺乳動物t細胞の活性化により誘導可能な合成プロモーター(syn+pro)の作製
Wahl et al. IL-20 receptor 2 signaling down-regulates antigen-specific T cell responses
JP2022519829A (ja) 組換え遺伝子発現を調節するための微小環境センサー
JP2013516194A5 (sl)
WO2009140206A1 (en) Improved expression of il-12 family heterodimers
Stevens et al. Biphasic transcriptional regulation of the interferon regulatory factor-1 gene by prolactin: involvement of gamma-interferon-activated sequence and Stat-related proteins.
Ghorbaninezhad et al. Tumor necrosis factor‑α in systemic lupus erythematosus: Structure, function and therapeutic implications
Ezernieks et al. The Human IgE Germline Promoter is Regulated By Interleukin‐4, Interleukin‐13, Interferon‐α and Interferon‐γ Via an Interferon‐γ‐Activated Site and Its Flanking Regions
US20240102047A1 (en) An oncolytic virus vector coding for variant interleukin-2 (vIL-2) polypeptide
ES2670894T3 (es) Promotor derivado de un gen humano
KR20220024495A (ko) 종양용해성 아데노바이러스 및 체크포인트 억제제 조합 요법
Tao et al. Interleukin-6 up-regulates the expression of interleukin-15 is associated with MAPKs and PI3-K signaling pathways in the human keratinocyte cell line, HaCaT
JP2021514187A (ja) キメラ抗原受容体の腫瘍環境特異的発現
KR20210042084A (ko) Hspa8 유전자의 프로모터
Kuhnert et al. Cloning, sequencing and partial functional characterization of the 5'region of the human p75 tumor necrosis factor receptor-encoding gene (TNF-R)
US20230100000A1 (en) Immune cell expressing adapter chimeric antigen receptor for sensing soluble antigens
Angkasekwinai et al. TH17 cytokines: characteristics, regulation, and biological function